Diminished RNA Primer Usage Associated with the L74V and M184V Mutations in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 Provides a Possible Mechanism for Diminished Viral Replication Capacity
Open Access
- 15 August 2003
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 77 (16), 8621-8632
- https://doi.org/10.1128/jvi.77.16.8621-8632.2003
Abstract
The emergence of drug resistance-conferring mutations can severely compromise the success of chemotherapy directed against human immunodeficiency virus type 1 (HIV-1). The M184V and/or L74V mutation in the reverse transcriptase (RT) gene are frequently found in viral isolates from patients treated with the nucleoside RT inhibitors lamivudine (3TC), abacavir (ABC), and didanosine (ddI). However, the effectiveness of combination therapy with regimens containing these compounds is often not abolished in the presence of these mutations; it has been conjectured that diminished fitness of HIV-1 variants containing L74V and M184V may contribute to sustained antiviral effects in such cases. We have determined that viruses containing both L74V and M184V are more impaired in replication capacity than viruses containing either mutation alone. To understand the biochemical mechanisms responsible for this diminished fitness, we generated a series of recombinant mutated enzymes containing either or both of the L74V and M184V substitutions. These enzymes were tested for their abilities to bypass important rate-limiting steps during the complex process of reverse transcription. We studied both the initiation of minus-strand DNA synthesis with the cognate replication primer human tRNA 3 Lys and the initiation of plus-strand DNA synthesis, using a short RNA primer derived from the viral polypurine tract. We observed that the efficiencies of both reactions were diminished with enzymes containing either L74V or M184V and that these effects were significantly amplified with the double mutant. We also show that release from intrinsic pausing sites during reverse transcription appears to be a major obstacle that cannot be efficiently bypassed. Our data suggest that the efficiency of RNA-primed DNA synthesis represents an important consideration that can affect viral replication kinetics.Keywords
This publication has 51 references indexed in Scilit:
- Mechanistic Studies to Understand the Progressive Development of Resistance in Human Immunodeficiency Virus Type 1 Reverse Transcriptase to AbacavirPublished by Elsevier ,2002
- Analysis of Efficiency and Fidelity of HIV-1 (+)-Strand DNA Synthesis Reveals a Novel Rate-limiting Step during Retroviral Reverse TranscriptionPublished by Elsevier ,2001
- Differential influence of nucleoside analog-resistance mutations K65R and L74V on the overall mutation rate and error specificity of human immunodeficiency virus type 1 reverse transcriptaseJournal of Biological Chemistry, 2000
- Resistance Profile of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Inhibitor Abacavir (1592U89) after Monotherapy and Combination TherapyThe Journal of Infectious Diseases, 2000
- Biochemical mechanisms involved in overcoming HIV resistance to nucleoside inhibitors of reverse transcriptaseDrug Resistance Updates, 2000
- Touching the heart of HIV-1 drug resistance: the fingers close down on the dNTP at the polymerase active siteChemistry & Biology, 1999
- Pre-Steady-State Kinetic Characterization of RNA-Primed Initiation of Transcription by HIV-1 Reverse Transcriptase and Analysis of the Transition to a Processive DNA-Primed Polymerization ModeBiochemistry, 1998
- Single-Step Kinetics of HIV-1 Reverse Transcriptase Mutants Responsible for Virus Resistance to Nucleoside Inhibitors Zidovudine and 3-TCBiochemistry, 1997
- Rapid Changes in Human Immunodeficiency Virus Type 1 RNA Load and Appearance of Drug-Resistant Virus Populations in Persons Treated with Lamivudine (3TC)The Journal of Infectious Diseases, 1995
- Structure-Activity Relationships Among a New Class of Antiviral Heterosubstituted 2',3'-Dideoxynucleoside AnaloguesNucleosides, Nucleotides and Nucleic Acids, 1995